Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | CTNNB1 |
Variant | R542H |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | CTNNB1 R542H lies within ARM repeat 10 of the Ctnnb1 protein (UniProt.org). R542H has been identified in sequencing studies (PMID: 27696107, PMID: 29500272), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Sep 2024). |
Associated Drug Resistance | |
Category Variants Paths |
CTNNB1 mutant CTNNB1 R542H |
Transcript | NM_001098210.2 |
gDNA | chr3:g.41234239G>A |
cDNA | c.1625G>A |
Protein | p.R542H |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_047447481.1 | chr3:g.41234239G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
XM_006712983 | chr3:g.41234260G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
XM_017005738.1 | chr3:g.41234239G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
XM_005264886 | chr3:g.41234239G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
XM_006712985 | chr3:g.41234239G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
NM_001098209.2 | chr3:g.41234239G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
XM_017005738.2 | chr3:g.41234239G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
XM_017005738 | chr3:g.41234239G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
NM_001098210 | chr3:g.41234239G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
XM_024453359.1 | chr3:g.41234260G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
XM_024453356.2 | chr3:g.41234239G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
XM_047447480.1 | chr3:g.41234239G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
XM_047447479.1 | chr3:g.41234239G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
XM_024453356.1 | chr3:g.41234239G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
XM_047447477.1 | chr3:g.41234239G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
XM_047447483.1 | chr3:g.41234239G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
NM_001330729.2 | chr3:g.41234260G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
XM_047447478.1 | chr3:g.41234239G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
XM_024453358.1 | chr3:g.41234239G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
NM_001098210.1 | chr3:g.41234239G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
XM_006712983.2 | chr3:g.41234260G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
NM_001904.3 | chr3:g.41234239G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
NM_001904 | chr3:g.41234239G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
NM_001904.4 | chr3:g.41234239G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
NM_001098210.2 | chr3:g.41234239G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
XM_006712984 | chr3:g.41234260G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
XM_006712985.1 | chr3:g.41234239G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
NM_001330729.1 | chr3:g.41234260G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
NM_001098209.1 | chr3:g.41234239G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
XM_006712985.2 | chr3:g.41234239G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
XM_047447482.1 | chr3:g.41234260G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
NM_001098209 | chr3:g.41234239G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
XM_024453360.1 | chr3:g.41234260G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
XM_024453357.1 | chr3:g.41234239G>A | c.1625G>A | p.R542H | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|